Exercise Training to Improve Cardiopulmonary Hemodynamics in Heart Failure Patients
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04909008 |
Recruitment Status :
Recruiting
First Posted : June 1, 2021
Last Update Posted : November 14, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Heart Failure Pulmonary Hypertension | Other: Exercise Training | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Randomized control trial |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Exercise Training to Improve Pulmonary Haemodynamic and Right Ventricular Function in Heart Failure Patients With Pulmonary Hypertension |
Estimated Study Start Date : | March 2023 |
Estimated Primary Completion Date : | March 2025 |
Estimated Study Completion Date : | December 2025 |

Arm | Intervention/treatment |
---|---|
Experimental: Exercise Training
Two sets of exercise testing (before and after) 10 weeks of supervised exercise training (3 sessions per week) at Mayo Clinic Florida.
|
Other: Exercise Training
10 weeks of supervised exercise training, 3 sessions per week at the cardiac rehab clinic at Mayo Clinic Florida.
Other Name: Cardiac Rehab |
No Intervention: Control Groups
Two sets of exercise testing while continuing with standard medical care in between.
|
- Maximal oxygen uptake (VO2max) measured in mL/kg/min [ Time Frame: 10 weeks ]VO2max is the maximal measured oxygen uptake during a symptom limited exercise test.
- Mean pulmonary arterial pressure (mPAP) measured in mmHg [ Time Frame: 10 weeks ]mPAP will be measured at rest and during exercise and is a measure of pulmonary vascular pressure.
- Pulmonary vascular resistance (PVR) measured in dynes [ Time Frame: 10 weeks ]PVR will be measured at rest and during exercise and is a measure of pulmonary hemodynamic function.
- Right ventricular contractile function measured as % fractional area change (RV FAC). [ Time Frame: 10 weeks ]RV FAC is a measure of overall contractile function of the right ventricle.
- Left ventricular contractile function measured as % fractional area change (LV FAC). [ Time Frame: 10 weeks ]LV FAC is a measure of overall contractile function of the left ventricle.
- Slope of the relationship between mean pulmonary arterial pressure and cardiac output (mPAP-Q slope) measured in mmHg/L/min. [ Time Frame: 10 weeks ]The mPAP-Q slope during exercise is a measure of the pulmonary hemodynamic response to exercise. A slope >3 is 'abnormal', and a steeper slope is related to poorer pulmonary hemodynamic function.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- NYHA functional class I-IIIb.
- LVEF < 40%.
- Clinically-stable for > 3 months [no change in disease status or medication].
- Willing and able to provide written informed consent and perform cycle-ergometer or treadmill based exercise.
Exclusion Criteria:
- NYHA class IV HF.
- Diagnosis of diastolic HF.
- Comorbidities such as obesity (BMI >36), uncontrolled systemic hypertension, type 2 diabetes, and COPD (FEV1 <50%).
- Musculoskeletal or other conditions that would limit exercise participation.
- Pregnant or nursing women

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04909008
Contact: Erika Douglass, MPH | (904) 953-6595 | douglass.erika@mayo.edu | |
Contact: Robyn Bryde, MD | (904) 953 -7274 |
United States, Florida | |
Mayo Clinic in Florida | Recruiting |
Jacksonville, Florida, United States, 32224 |
Principal Investigator: | Bryan J Taylor, PhD | Mayo Clinic |
Responsible Party: | Bryan Taylor, Principal Investigator, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT04909008 |
Other Study ID Numbers: |
20-011347 |
First Posted: | June 1, 2021 Key Record Dates |
Last Update Posted: | November 14, 2022 |
Last Verified: | November 2022 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Exercise training Right ventricle Exercise capacity Quality of life |
Hypertension, Pulmonary Hypertension Heart Failure Vascular Diseases |
Cardiovascular Diseases Heart Diseases Lung Diseases Respiratory Tract Diseases |